Now New York is refusing monoclonal antibodies for white people.
Tuesday, January 04, 2022 by: Ethan Huff
In an official announcement issued to health care providers and facilities across the state, the department explained that there is a “severe shortage” of the oral antiviral drugs Paxlovid (Pfizer) and molnupiravir (Merck) that requires rationing.
Molnupiravir, by the way, was recently discovered to cause cancerous mutations in test mammals.
“Paxlovid and molnupiravir reduce the risk of hospitalization and death by 88% and 30% respectively, in patients at high-risk for severe COVID-19 when started early after symptom onset,” the announcement states without evidence.
The only monoclonal antibody treatment said to be effective against the new Omicron (Moronic) variant of the Wuhan coronavirus (Covid-19) is also in short supply.
“There will be a pause on allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV beginning 1/3/2022,” the announcement further explains.
Because of all this, the department is limiting availability of these drugs only to non-whites, unless a white person has “a medical condition or other factors that increase their risk for severe illness.”
“Non-white race or Hispanic / Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19,” the announcement explains about the racist new policy.
Are whites better off not getting these experimental treatments?
What this language suggests, of course, is that non-whites are inherently a risk factor simply because of the color of their skin.
“Could they be any more insulting to minorities?” asked one commenter at Twitter (though it is important to clarify that whites are rapidly becoming the new minority in America, and are already a minority when looking at global population statistics).
“‘No, we won’t resolve systemic health and social inequities, but you can cut the line for treatment that is unlikely to fully protect,’” this same person further joked about what the New York State Department of Health is really saying with its racist announcement.
This type of this is happening even in “red” states, just to be clear. Texas, as we recently reported, is seeing some of its health systems ration out monoclonal antibody treatments only to non-whites.
It is almost like some kind of memo is circulating within the corporate “health care” machine that runs this country instructing practitioners to openly discriminate against people with light skin.
None of this is to say that the drugs in question are truly safe and effective, just to be clear. Perhaps white people (and all people) are better off not taking these experimental medications in the first place.
What it does say, however, is that health care discrimination against whites is starting to “trend,” and must be nipped in the bud before it advances any further.
“I do not trust the antibody treatment,” wrote one commenter at Natural News about “passive vaccination,” which is another name for monoclonal antibodies. “Better off with nutritional intake and natural anti-virals.”
“You seem to be falling into the trap of conflating ‘all men are created equal’ into ‘all men are created the same,’” wrote another commenter, offering a different perspective as to what might be going on here with all of this.
“If the science indicates one group has a greater benefit from a treatment and the other has very little, shouldn’t the group with the greater benefit have priority. Are thin people also being discriminated against?”
The latest news about the Wuhan coronavirus (Covid-19) can be found at Pandemic.news.
Sources for this article include: